<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327391</url>
  </required_header>
  <id_info>
    <org_study_id>UF 7753</org_study_id>
    <nct_id>NCT01327391</nct_id>
  </id_info>
  <brief_title>Tolerance of &quot;on Line&quot; Hemodiafiltration in Chronic Renal Failure Patients</brief_title>
  <acronym>on-line-HDF</acronym>
  <official_title>Tolerance of &quot;on Line&quot; Hemodiafiltration and Impact on Morbidity and Cardiovascular Risk Factors in Chronic Renal Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to appreciate the tolerance of &quot;on line&quot; hemodiafiltration and its
      impact on morbidity and cardiovascular risk factors in chronic renal failure patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to appreciate the tolerance of &quot;on line&quot; HDF treatment versus
      conventional high flux hemodialysis in term of adverse events occuring during dialysis
      sessions between day 30 and day 120 of treatment and to evaluate:

        -  Quality of life evaluated with the KDQOL questionnaire

        -  Incidence of cardiovascular events

        -  Influence of the technic on cardiovascular, inflammatory and infectious risk factors

        -  Mortality
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tolerance of &quot;on line&quot; HDF treatment versus conventional high flux hemodialysis in term of adverse events occuring during dialysis sessions</measure>
    <time_frame>between day 30 and day 120 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated with the KDQOL questionnaire</measure>
    <time_frame>day 0, 180, 365, 730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular events</measure>
    <time_frame>day 180, 365, 730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of the technic on mineral metabolism disturbances</measure>
    <time_frame>day 180, 365, 730</time_frame>
    <description>measure of mineral metabolism parameters (Ca, PO4, PTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause and cardiovascular mortality</measure>
    <time_frame>day 180, 365, 730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of the technic on inflammatory parameters</measure>
    <time_frame>day 180, 365, 730</time_frame>
    <description>measure of pro-inflammatory cytokines and acute phase reactant proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of the technic on microbiological safety</measure>
    <time_frame>day 180, 365, 730</time_frame>
    <description>measure of microbiological purity of dialysate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of the technic on oxidative stress parameters</measure>
    <time_frame>day 180, 365, 730</time_frame>
    <description>measure of oxidative stress markers (AOPP, AGE) and antioxidant systems (vitamin E)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>On line Hemodiafiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hemodialysis patients treated with on line hemodiafiltration technic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hemodialysis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>On line Hemodiafiltration</intervention_name>
    <description>3 sessions/week; 3-4 hours per session</description>
    <arm_group_label>On line Hemodiafiltration</arm_group_label>
    <other_name>on line HDF</other_name>
    <other_name>HDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemodialysis</intervention_name>
    <description>3 sessions/week; 3-4 hours per session; high flux dialyzers</description>
    <arm_group_label>hemodialysis</arm_group_label>
    <other_name>conventional hemodialysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who has signed the written consent form

          -  Patient aged &gt; 65 and &lt; 90 years

          -  With creatinine clearance &lt; 10 mL/min

          -  On dialysis for a minimum of 3 months, with 3 times a week hemodialysis sessions

          -  Erythropoietin dosage needed to maintain hemoglobin at a constant level (range of
             hemoglobin: 9-13 g/dL without any variation of more than 2g/dL for less than 3 months)

          -  Without any problem of vascular access

        Exclusion Criteria:

          -  Patient aged &lt; 65 and &gt; 90 years

          -  Presence of severe malnutrition (albumin &lt; 20 g/L)

          -  Unstable clinical condition

          -  Unipuncture or failed vascular access flow

          -  Known problems of coagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier AGUILERA, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHG Vichy France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynda AZZOUZ, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CH Roanne France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marie BATHO, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CH privé Saint Martin Caen France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois COMBARNOUS, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique du Tonkin Villeurbanne France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lotfi CHALABI, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>AIDER Montpellier France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy DEGREMONT, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHG Cambrai France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maxime HOFFMANN, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique de la Louvière Lille France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gérard DESCHODT, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>AIDER Nimes France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Assia DJEMA, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHG Cholet France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain DUBOUST, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique du Vert Galant, Tremblay en France, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre DUMOULIN, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHLM Beziers France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baya FADEL-BABBA, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>AGDUC La Tronche France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique FIGUEROA, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CH Briancon France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry HAAS, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CMCO Evry France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Michel HARDIN, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CH Soissons France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel HILLION, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHI Poissy France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillaume JEAN, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CRAT Tassin La Demi Lune France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Véronique JOYEUX, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Pontchaillou Rennes France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian KUNZ, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>AURAL France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine LACAILLE, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>UNHEP Aulnay sous Bois France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques LEBLEU, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique néphrologique Pont Allant Maubeuge France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent LEMAITRE, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHG Valenciennes France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehadji MAAZ, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CH Louis Pasteur Colmar France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe NICOUD, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique Centre Vallée Blanche Chamonix France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Paul ORTIZ, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Polyclinique Saint Roch Cabestany France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacky POTIER, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CH Louis Pasteur Cherbourg France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier PUYOO, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique Néphrologique Occitanie Muret France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Véronique QUERON, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Polyclinique Francheville Perigueux France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles SCHUTZ, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Centre HD Provence Aubagne France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois MAURICE, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHLM Montpellier France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno SEIGNEURIC, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Larrey Toulouse France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederic TOLLIS, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Angers France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos VELA, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CH Perpignan France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois WAMBERGUE, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique du Bois Lille France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian WOLF, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>CH Toulon France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Paul CRISTOL, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Lapeyronie Montpellier France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard CANAUD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lapeyronie Montpellier France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>on line hemodiafiltration</keyword>
  <keyword>tolerance</keyword>
  <keyword>quality of life</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>Hemodialysis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

